SCHEMBL654864

SCHEMBL654864

CCCOC(=O)c1cc2c(o1)c(NC(=O)c1ccc(N3CCN(C)CC3)cc1[N+](=O)[O-])nn2C(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 8/20 0.42
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
HTR6 P50406 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 3/20 0.37
GLA P06280 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PLK1 P53350 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083005 0.86 MAPT (0.44) MAPTRAB9A
SCHEMBL653045 0.85 ALDH1A1 (0.52) MAPTLMNAPOLBL3MBTL1ALDH1A1
SCHEMBL3880690 0.79 MAPT (0.46) MAPTRAB9A
SCHEMBL4091205 0.79 LRRK2 (0.46) MAPTLMNAL3MBTL1MAPK1ALDH1A1
SCHEMBL4082722 0.77 RAB9A (0.43) MAPTLMNAL3MBTL1MAPK1RAB9A
SCHEMBL4084026 0.76 MAPT (0.42) MAPTLMNAPOLBMAPK1ALDH1A1
SCHEMBL4084062 0.76 ALDH1A1 (0.51) MAPTPOLBMAPK1ALDH1A1RAB9A
SCHEMBL1781045 0.76 SIRT6 (0.42) SIRT6MAPTLMNAPOLBHTR6
SCHEMBL4083791 0.75 LMNA (0.44) MAPTLMNAPOLBL3MBTL1ALDH1A1
SCHEMBL1987021 0.75 SIRT6 (0.42) SIRT6MAPTLMNAPOLBHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119641-B2 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-21 US disclosed
EP-2051981-B1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2010-08-25 EP disclosed
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-09-24 US disclosed
EP-2051981-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2009-04-29 EP disclosed
WO-2007138017-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS IGF1R, CDK1, CDK15 SIRT6 2330/4885MAPT 365/4885LMNA 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.